09.12.2009 • Topics

Sanofi Spending €350 Million on Vaccine Site

France's Sanofi-Aventis is spending €350 million to build a site to produce a potential blockbuster dengue vaccine that is still in development. The high-technology site should be up and running in 2013 to produce 100 million doses of the dengue vaccine which should become available in 2014 in the endemic regions such as Asia Pacific. The new plant will be located in Neuville-sur-Saone, near Sanofi Pasteur's headquarters in Lyon, France. Sanofi has 12 manufacturing sites under construction or undergoing major renovation and they will come on line in 2009. Among them is the recently approved U.S. factory in Pennsylvania, which is to produce the seasonal flu vaccine Fluzone.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.